Academic, Collaborations, Competitor News

TriNetX Develops New Analytics Course with The University of Texas Medical Branch

Course Focuses on Integrating the Use of TriNetX with Biomedical Informatics Curriculum CAMBRIDGE, Mass., Aug. 10, 2022 /PRNewswire/ — TriNetX, LLC partnered with The University of Texas Medical Branch (“UTMB”) on a new research and analytics course titled: Biomedical Informatics: Applied Investigation and Analysis in Health Outcomes Research. The course aims to provide theoretical and practical experience…

Competitor News, Pharma, RWE Study

Pear Therapeutics Announces Publication of New Analysis of Real-World Data Showing Reduction in Insomnia Severity, Healthcare Resource Utilization and Associated Costs in Adults Using Somryst®

August 10, 2022 04:02 PM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the publication of new results from a health economic analysis of real-world data to evaluate healthcare resource utilization, associated costs and insomnia…

AI, Collaborations, Competitor News, Pharma

Saama Collaborates with Merck to Build Machine Learning-Powered Clinical Data Layer to Strengthen Merck’s Clinical Development Capabilities

August 10, 2022 08:00 AM Eastern Daylight Time CAMPBELL, Calif.–(BUSINESS WIRE)–Saama Technologies, LLC. (“Saama”) today announced a multi-year agreement with Merck, known as MSD outside the United States and Canada, to build and operationalize a new clinical data layer leveraging Saama’s Life Science Analytics Cloud (LSAC) to strengthen Merck’s clinical development capabilities and expedite…

Collaborations, Competitor News, Data Partnership, Oncology, RWE Study

Initial Analysis of Tumor Profiling From a Prospective Study by Foundation Medicine, Flatiron Health and Genentech Demonstrates Value of Tissue and Liquid Comprehensive Genomic Profiling in Patients with Advanced Non-Small Cell Lung Cancer

The ongoing real-world Prospective Clinicogenomic (PCG) Study compares the clinical actionability of both tissue- and blood-based comprehensive genomic profiling to limited tissue testing in this patient population August 08, 2022 07:05 AM Eastern Daylight Time CAMBRIDGE, Mass. & NEW YORK–(BUSINESS WIRE)–Foundation Medicine, Inc., Flatiron Health, and Genentech, members of the…

Collaborations, Competitor News, Data Partnership, Oncology, RWE Study

Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer

August 08, 2022 06:15 AM Eastern Daylight Time PALO ALTO, Calif., & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Guardant Health Inc. (Nasdaq: GH), a leading precision oncology company, and Blueprint Medicines Corporation (Nasdaq: BPMC) announced today they are presenting new data demonstrating that the EGFR C797X mutation is the most common resistance mechanism to…